

# Patent Certifications and Suitability Petitions

FDA aspires to continually improve its pre-ANDA (abbreviated new drug application) interactions with applicants. To facilitate these interactions and keep stakeholders as informed as possible, the agency regularly publishes information on suitability petitions and Paragraph IV patent certifications.

- [Paragraph IV Patent Certifications](#)
- [Paragraph IV Certifications List](#)
- [New Paragraph IV Certifications as of September 26, 2017](#)
- [Suitability Petitions](#)
- [Contact Us](#)

## Paragraph IV Patent Certifications

Under the [Drug Price Competition and Patent Term Restoration Act of 1984 \(https://www.congress.gov/bill/98th-congress/senate-bill/01538\)](https://www.congress.gov/bill/98th-congress/senate-bill/01538), also known as the Hatch-Waxman Amendments, a company can seek FDA approval to market a generic drug before the expiration of patents related to the brand-name drug that the generic seeks to copy. To seek this approval, a generic applicant must provide in its application a "certification" that a patent submitted to FDA by the brand-name drug's sponsor and listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) is, in the generic applicant's opinion and to the best of its knowledge, invalid, unenforceable, or will not be infringed by the generic product. This certification is called a "paragraph IV certification." The first company or companies to submit an application that (1) is determined by the agency to be "substantially complete" upon submission and (2) contains a paragraph IV certification to at least one of the patents listed in the Orange Book is generally eligible for the exclusive right to market the generic drug for 180 days.

In order to challenge a patent in court, the generic applicant that submitted a paragraph IV certification must notify the brand product sponsor and any patent holder of the submission of the ANDA and patent challenge. If the brand product sponsor or patent holder files an infringement suit against the generic applicant within 45 days of the ANDA notification, FDA approval to market the generic drug is generally postponed for 30 months unless the patent expires or is judged to be invalid or not infringed before that time. This 30-month postponement, commonly referred to as the "30-month stay," gives the brand product sponsor and patent holder a prescribed amount of time to assert patent rights in court before a generic competitor is approved and can market the drug.

[Back to Top](#)

## Paragraph IV Certifications List

As part of its ongoing efforts to assist generic drug applicants in preparing their applications, FDA regularly publishes a [list of drug products for which an ANDA has been received by the Office of Generic Drugs \(OGD\) containing a Paragraph IV patent certification \(downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf\)](#) (PDF - 476KB). This list includes the name of the drug product, dosage form, strength, reference listed drug (RLD), and the date on which the first substantially complete generic drug application was submitted to the agency that contained a paragraph IV certification (on a prospective basis, beginning March 2, 2004). The agency will not disclose the identity of the applicant(s). The Agency will make every effort to ensure the accuracy of the information disclosed in this list. However, before making any decisions based on this information, any discrepancies or disparities should be discussed with the Patent and Exclusivities Team (PET) by emailing [CDER-OGDPET@fda.hhs.gov \(mailto:CDER-OGDPET@fda.hhs.gov\)](mailto:CDER-OGDPET@fda.hhs.gov).

[Back to Top](#)

[New Paragraph IV Certifications as of September 26, 2017](#)

DRUG NAME	DOSAGE FORM	STRENGTH	RLD	DATE OF SUBMISSION
Abacavir Sulfate, Dolutegravir and Lamivudine	Tablets	600 mg/50 mg/300 mg	Triumeq	8/14/2017
Deferasirox	Tablets	180 mg	Jadenu	4/28/2016
Efavirenz	Capsules	50 mg, 100 mg and 200 mg	Sustiva	11/3/2016
Emtricitabine	Capsules	200 mg	Emtriva	7/16/2012
Icosapent Ethyl	Capsules	500 mg	Vascepa	8/29/2017
Levomilnacipran	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	Fetzima	7/25/2017

#### Additional Resource

- [Paragraph IV Patent Certifications \(PPIV\) \(\[/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf\]\(#\)\)](#) as of September 26, 2017 (PDF - 716 KB)

#### Back to Top

#### Suitability Petitions

Under the Hatch-Waxman Amendments (<https://www.congress.gov/bill/98th-congress/senate-bill/01538>), a generic applicant may petition FDA for permission to file an ANDA for a drug product that differs from a listed drug in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) with respect to the following characteristics: route of administration, dosage form, strength, or active ingredient in a combination drug product that contains multiple active ingredients. These petitions are referred to as "suitability" petitions.

A generic applicant cannot submit an ANDA for such a product until FDA has approved the related petition. The grounds for FDA approval of such a petition are set out in 21 CFR 314.93(e). The determination that an ANDA will be approved is not made until the ANDA itself is submitted and is reviewed by the agency. A copy of each petition is listed by docket number on public display in FDA's Division of Dockets Management, 5630 Fishers Lane, Room 1061, HFA-305, Rockville, MD 20852.

FDA aspires to respond to suitability petitions in a timely, predictable manner and to provide the public with updates regarding filed petitions.

#### Filed Petitions

The following are abbreviated lists of petitions filed after March 31, 1999, under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act, for which the agency has determined that (1) the product proposed in the petition is suitable for submission as an ANDA (Petition Approved); (2) the product proposed in the petition is not suitable for submission as an ANDA (Petition Denied); (3) the petition has been withdrawn (Petition Withdrawn); or (4) the petition is still pending (Petition Pending).

- [OGD Suitability Tracking Report Sorted by Drug Name \(\[/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM458481\]\(#\)\)](#) (PDF – 1.3MB) (updated August 2014)
- [OGD Suitability Tracking Report Sorted by Petition Number \(\[/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM458482\]\(#\)\)](#) (PDF – 1.3MB) (updated August 2014)

**[Back to Top](#)**

**Contact Us**

Questions about suitability petitions can be directed to  
FDA's Division of Dockets Management  
5630 Fishers Lane  
Room 1061, HFA-305  
Rockville, MD 20852

**[Back to Top](#)**